I t has only been in the past couple of decades that the weight of evidence led to formal pronouncement of atherosclerosis as an inflammatory disease 1,2 rather than solely a disease associated with aberrant cholesterol accumulation and handling. Inflammation in general is driven by activation of the endothelium and leukocyte trafficking across this endothelial barrier to supply the reacting tissue with effector cells. The dominant leukocyte type recruited to atherosclerotic plaque is the monocyte. Early studies that connected the dots between atherosclerosis and inflammation recognized the primary importance of lesional macrophages, recruited as monocytes into developing plaques, 1 where they take up large amounts of cholesterol to generate so-called foam cells filled with numerous cholesterol ester droplets. Macrophages are not only major cells that sequester cholesterol within plaques, but they are also implicated in critical events of clinical significance, particularly plaque rupture. 3, 4 For example, macrophage presentation of antigen to T lymphocytes may support the generation of conditions conducive to plaque rupture, among antigen-presenting cells raises the possibility that other types of mononuclear phagocytes (MPs), such as dendritic cells (DCs), may be as or more relevant to any interactions with lymphocytes that in turn drive disease.
Researchers attempting to understand in detail the role of MPs in initiating and sustaining atherosclerosis, with the goal of learning how to reverse these events, face challenges that include anatomic, technical, and temporal constraints. Anatomically speaking, the location of plaques deep in the chest cavity near the beating heart and respiratory system raises great challenges for intravital imaging. Technical challenges are many including limitations on the interpretation of the powerful technique of flow cytometry because flow cytometry obliterates the ability to distinguish intimal leukocytes from those in the adventitia. Temporal constraints include the slow pace that the disease develops under the most physiological conditions, decades in man and months in mice. Finally, the deadliest stage of the disease in man, plaque rupture, has no widely accepted counterpart in experimental models, limiting our ability to focus on key events in an experimental scenario. With all these drawbacks, the need to better understand the mechanisms of atherosclerosis remains and the role that MPs play, as it remains a leading cause of mortality worldwide. These techniques, outlined with their inherent pros and cons in Table 1 , are responsible for progress in the field and underlie my discussion in this review on the status of our knowledge about MPs in atherosclerotic plaques, including how the accumulation of MPs is triggered and regulated during disease progression and whether these mechanisms can be reversed to bring about disease regression. With all the valuable insight these approaches have provided, it is important to keep in mind the caveats of the methods when interpreting the results from the techniques used.
Preplaque and Early Atherosclerotic Plaque:
Vascular Dendritic Cells?
Leukocyte trafficking into inflamed tissue occurs through specific activation of endothelium. The formation of atherosclerotic plaques requires activation of arterial endothelium, breaking with the more typical restriction of endothelial cell activation to postcapillary venules within the vascular bed. This activation is characterized by induction or upregulation of adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 and chemoattractants, including lipids such as platelet-activating factor and chemokines such as interleukin-8 (IL-8; cysteine-cysteine chemotactic ligand [CCL]8) or monocyte chemoattractant protein 1 (CCL2). Endothelial cell activation is a prerequisite to the formation of atherosclerotic plaques that preferentially form along the arterial tree at sites that experience reduced shear stress as a result of arterial curvature and branching. This activation of endothelium is inherently persistent because it results from the anatomy of the arterial tree. Consequently, a persistent inflammatory response ensues. 11 However, this response is self-limited and quickly reaches a state of maintenance that does not expand the inflammatory reaction beyond MPs that are recruited to reside in a single, discontinuous layer under the endothelium. 11 The pattern of distribution of these MPs is morphologically reminiscent of cells such as Langerhans cells in the skin that form a network in the epidermis. Mouse, rabbit, and human arteries all seem to develop these vascular MP networks at sites predisposed to atherosclerosis, although the data in human and rabbit are more limited. Current phenotypic characteristics of prelesional MPs from the different species are listed in Table 2 .
Distribution of these MPs is limited to areas of basal endothelial activation that correspond to hemodynamic stress. 11, 30 The natural seeding of these sites by MPs occurs by the earliest point in time investigated to date, when the mice are 4 weeks old. 32 It would be interesting to know if the cells are recruited much earlier, perhaps before birth. Although more information on the life cycle of these cells is needed, some interesting findings are known. The lifecycle of these vascular MPs is dependent on their expression of CX3CR1. 32 VCAM-1 deficiency leads to a 50% reduced density of the MPs. 11 This finding suggests that their initial seeding may be dependent on endothelial cell activation and that, likely, they are continuously recruited at least to some extent. However, VCAM-1 can also be expressed by MPs, so it is possible that deficiency of VCAM-1 as a means to lower the density of these cells targets the MPs themselves rather than the endothelium. Furthermore, if deficiency of VCAM-1 indicates that the MP are recruited across the endothelium, it is not clear if the key recruitment occurs prenatally or postnatally. Nor is there information on the rate of turnover of the cells. The expression of Langerin on the vascular MP in humans suggests the cells might share features with Langerhans cells, the specialized DCs that reside in the epidermis. 34 In mice, maintenance of Langerhans cells depends completely on local proliferation, 34 and this may also be true at least to some extent in man. 34 A low level of proliferation of the vascular MP also occurs, and perhaps the extent of proliferation is sufficient to sustain them, but relatively low number of total MPs within the mouse aorta preclude finely tuned analysis in the absence of hypercholesterolemia. 33 Thus, it remains unclear whether their life cycle is sustained by continuous recruitment or proliferation or both. In any case, because the density of arterial MPs increases only slowly over a lifetime without induction of hypercholesterolemia, 32 the low-grade inflammatory response that the accumulation of these MPs seem to represent might alternatively be considered a new homeostasis in sites of hemodynamic stress.
What do these preplaque MPs have to do with atherosclerosis? From the current literature, one can make a case that these cells promote atherosclerosis. First, the basal density that they reach is not only controlled by VCAM-1, but expression of VCAM-1 in turn seems to be controlled by activation of the inflammasome within the endothelium through a mechanism dependent on sterol element regulatory-binding protein 2. 35 The induction of this pathway, even in the absence of hypercholesterolemia, is strikingly similar to pathways that promote progression of atherosclerosis. Furthermore, the presence of preplaque MPs beneath the arterial endothelium not only predicts where plaques will form but the density of these MP varies among mouse strains in proportion to the susceptibility of that strain to atherosclerosis. That is, mice whose genetics predisposes them to atherosclerosis have a higher basal density of these cells. 11 Within 1 to 2 weeks after hypercholesterolemia is induced in mice, via feeding low density lipoprotein receptor (LDLR −/− ) mice a cholesterol-enriched diet, these cells acquire neutral lipids and they proliferate rapidly in a granulocyte-macrophagecolony stimulating factor-dependent manner. 33 If these cells are depleted from mice before the onset of hypercholesterolemia, less cholesterol accumulates in the artery wall at early time points and what does arrive remains extracellular, 36 suggesting that they actively participate in bringing lipid into nascent atheromata. Furthermore, atherosclerosis is attenuated in mice lacking CX3CR1, 32 where these MPs are reduced, but the other roles of CX3CR1 in atherosclerosis including control of monocyte recruitment 27 and survival 37, 38 preclude the possibility of knowing whether the loss of preplaque vascular MPs is a major reason for reduced atherosclerosis in CX3CR1-deficient mice.
It is unlikely that the accumulation of these cells in areas of endothelial activation along the arterial tree has evolved to promote atherosclerosis. It seems more reasonable to envision that the positioning of these MPs where they sit in the artery wall provides some benefit to the host. Their ability to pick up lipids from the bloodstream does not end there; they also acquire soluble proteins introduced as model antigens from the bloodstream. 39 Furthermore, immune complexes readily accumulate in the intima of arterial sites exhibiting branches and bifurcations. 40 Thus, perhaps the arterial accumulation of intimal MPs evolved to protect surfaces of the vasculature where the hemodynamics might allow for antigens, possibly even pathogens, to buildup. The presence of MP there would allow antigens or pathogens to be better detected and captured. In this scenario, the primary role of these cells is to serve as immune sentinels of the bloodstream.
Accordingly, these MP are efficient antigen-presenting cells, capable of potently activating naive T cells with specificity against antigens they have acquired from plasma. 39 In line with this function, they express some of the molecular features of DCs rather than macrophages (Table 2) . These features include expression of CD11c and C-type lectin 4A4 (also known as 33D1) in the mouse and expression of Lag-1, a Langerhans cells marker, in humans. They express little CD11b, suggesting that they are not monocytes. However, they do express high levels of CD68, which is more abundant in macrophages than DCs, although not absent, particularly at the mRNA level, in DCs. 41 Two major subsets of DCs are found in many nonlymphoid organs, 42 one subset that expresses CD11b as abundantly as monocytes. These CD11b + DC are depend on the transcription factor interferon response factor 4. [43] [44] [45] [46] The other subset of DCs expresses the α7 integrin CD103. This subset of DCs represents efferocytic, cross-presenting DCs that developmentally depend on the transcription factor basic leucine zipper transcription factor ATF-like 3.
42 CD103 + DCs have been identified in the heart and aorta using flow cytometry in wild-type mice without atherosclerosis. 7 Currently, it remains unclear whether CD103 + DCs account for the DCs that line preplaque sites because research efforts to align data from in situ imaging and flow cytometry have not yet been published. Given that the preplaque proliferating DCs express little CD11b, it is possible that they are CD103 + DCs, but expression of 33D1 seems inconsistent with this possibility. In addition to requiring basic leucine zipper transcription factor ATF-like 3 for development, this subset of DCs shares with all other DCs dependence on the cytokine Flt3 for development or maintenance. Based on this dependence, it has been argued that arterial CD103 + DCs promote T-regulatory cell activity and thereby maintain an anti-inflammatory state in the arterial wall. 7 This interesting concept needs further development because Flt3 has a multitude of biological actions. If CD11b − DCs that acquire cholesterol in early plaque are the same DCs as CD11b − CD103 + DCs identified in single aortic cell isolations, which seems unlikely based on 33D1 staining being normally absent in CD103 + DCs, one might argue that their acquisition of cholesterol is proatherogenic but that they may also suppress atherosclerosis by supporting anti-inflammatory state rich in T-regulatory cells. 7 Functionally, DCs and macrophages have different roles in tissue where they have been studied. Macrophages seem to orchestrate tissue function and response to injury. 47 They are more likely to degrade phagocytic cargo quietly in an attempt to maintain homeostasis, whereas DC biology favors actions that promote presentation of peptides from phagocytic cargo on major histocompatibility complex molecules to drive T-cell responses. Accordingly, DCs are triggered en masse by inflammatory stimuli to rapidly (within 24 hours) emigrate from tissues to draining lymph nodes, an event that brings them to the right location for interacting with naive T cells. 48 Macrophages poorly emigrate from tissues, especially resident macrophages. For example, in the lung, resident macrophages take up the vast majority of foreign matter that enters the airway, but they are, on a per cell basis, ≥100× less efficient than DCs in emigrating to lymph nodes. 49 Monocytes newly recruited to tissues, however, are more capable of trafficking to lymph nodes, 50 although they still are poor compared with DCs, being outnumbered by DCs 10:1 in antigen transport to lymph nodes even under conditions when monocytes are as or more numerous than DCs in the organ. 50 Furthermore, molecules involved in handling cholesterol, such as ATP-binding cassette (ABC) A1 and ABCG1, are also differentially expressed by macrophages and DCs; high levels of ABCG1 characterize lymph node-homing DCs (http://www.immgen.org), but ABCA1 is preferentially restricted to macrophages. 41 If these MPs are DCs, then it must be said that DCs are instrumental in the earliest stages of atherosclerosis, arriving even earlier than the canonical macrophage foam cell.
Overall, more characterization of preplaque MPs is needed, including whether they are derived from monocytes, derived from dedicated DC precursors from the bone marrow, or derived from embryonic MPs. 42 Defining the developmental aspect of their life cycle is important because doing so would be expected to provide new insight into function and ultimately better manipulation of the cell, knowledge that might be fundamental for defining new ways to manipulate atherosclerotic plaque. Questions of whether and where DCs act as contributors to atherosclerosis cannot be adequately addressed until we have a better understanding of the role that the adaptive immune response plays in atherosclerosis. Although cytokines including interferon γ and IL-17 produced by T lymphocytes seem to contribute to atherosclerosis, 51 whether their production is exclusively derived from T lymphocytes and whether they are secreted downstream of an antigen-driven response remains unclear. T-regulatory cells, for example, have a pivotal role in atherosclerosis, 52 but recent data suggest that they do so by primarily modulating lipoprotein profiles. 53 The overall effect of T-cell deficiency on atherosclerosis is ultimately minor 54 and cannot always be separated from effects on plasma cholesterol because lower cholesterol was observed in atherogenic backgrounds lacking lymphocytes under conditions when disease was reduced. 55 
Plaque Progression Monocyte Subsets and Recruitment to Plaques
In the LDLR −/− model of experimental atherosclerosis, the growth of atherosclerotic plaque beyond the sentinel, subendothelial MPs can be observed within 2 weeks after introducing cholesterol in the diet. It is at this point that there is a robust influx of monocytes into plaques that triggers fatty streak formation and drive plaque progression. The earliest studies that implicated the monocyte as the critical source of foam cells used crude tools for identifying them. 56 In the past decade, better characterization has emerged, with mouse models leading the way. Strategies based on negative or positive gating in flow cytometry to distinguish monocytes, macrophages, and DCs have been developed. 50 We have favored the identification of monocytes in the mouse circulation using staining for CD115, the receptor for colony stimulating factor 1, sufficient to identify monocytes on its own or when stained in combination with F4/80. 27, 57 Use of this strategy along with staining for Ly-6C (sometimes called Gr-1 because of an antiGr-1 mAb that recognizes a common epitope on Ly-6C and Ly-6G) 58 allows separation of monocytes into 2 subsets, similar to identification of monocytes in CX3CR1 gfp/+ mice.
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The Ly-6C + subset is especially significant because it expresses chemotactic cytokine receptor 2 and shows an overall gene expression profile that closely matches the majority of human blood monocytes. 60 When this subset is isolated to purity, labeled with radioactive indium, and injected into mice, it becomes apparent that these monocytes are recruited to atherosclerotic plaques, with recruitment proportional to disease burden. As an alternative approach, we developed a technique to label this subset of monocytes with fluorescent polystyrene particles. 27 In agreement with the adoptive transfer technique, the method shows that this subset of monocytes is highly recruited to atherosclerotic plaques, and hypercholesterolemia increases its recruitment. 27 Blood monocytes in all species are heterogeneous. 61 In the mouse, the Ly-6C − subset, a derivative of Ly-6C + monocytes that differentiate in the bloodstream, accounts for about half of blood monocytes. It possesses a gene expression profile that strongly overlaps with CD16 + human monocytes, including expression of CD16 itself. 60 However, its human counterpart represents the vast minority of blood monocytes, typically not more than 5% to 10% of total circulating monocytes. The Ly-6C − monocyte subset is recruited into atherosclerotic plaques but to a lesser extent than Ly-6C + monocytes, 17, 27 and its signature biological role has been mysterious for years. Recent data indicate that its lifecycle is predominantly spent within the vasculature itself. It makes intimate contact with the apical surface of the endothelial interface in vivo, where it is appropriately positioned to react to endothelial damage and preserve vascular function. 62 Accordingly, mice lacking this subset because of a deficiency in the transcription factor Nr4a1 that regulates its development/maintenance have more severe atherosclerosis, 63, 64 fitting with a vascular protective role, although vascular status was not monitored in these studies. The Nr4a1 −/− mouse has other defects including changes in macrophage phenotype unrelated to loss of Ly-6C − monocytes. Furthermore, other laboratories have been unable to confirm these results. 65 Nonetheless, the concept that Ly-6C − monocytes promote vascular stability and thereby serve an atheroprotective role is a working model for the field at the present time.
Though similar to human CD16 + monocytes, a few differences between the mouse and human CD16 + monocyte counterparts are worth mentioning. It remains unclear whether human CD16 + monocytes are atheroprotective. I have already mentioned the relative difference in proportion of these cells in humans compared with mice. Would an increase in these cells provide an increased measure of vascular stability? For years, the argument has been put forward that the tendency of CD16
+ human monocytes to increase in inflammatory disease might implicate a role in disease. 61 Instead, this change might be a protective response that defends the host during vascular stress. In the mouse, however, this subset is also equipped with genes that reveal its role as a sensor and responder to cholesterol, through expression of genes including CD36, peroxisome proliferator-activated protein γ, and ABCA1. 60 This expression profile is not obviously recapitulated in CD16 + human monocytes, raising the possibility that the role of this monocyte subset in cardiovascular disease differs between the 2 species. However, likely core roles are similar. Human CD16 + monocytes in culture will, even after traversing endothelium, return to the apical endothelial surface, seemingly displaying a preference for this position along even cultured endothelium. 66 Monocytes are well known to differentiate to macrophages, and the prevailing paradigm is that monocytes become macrophages in atherosclerotic plaques. Potential modifiers of this paradigm, including the proliferation of macrophages, will be discussed below. How can one distinguish the newly recruited monocytes in plaque from macrophages, and both of these from DCs? In many tissues of mice, a strategy that we recently identified from a large-scale expression profiling analysis seems useful. Mer tyrosine kinase and the high-affinity Fcγ receptor CD64 are among a handful of genes that distinguish macrophages from DCs.
41 CD64 is also expressed on monocytes. 60 Thus, it may be suitable to use these new markers in flow cytometric evaluations 50 of aortic cells to aid in distinguishing monocytes, macrophages, and DCs. 41 
Size of the Blood Monocyte Pool Correlates With Atherosclerosis: Mechanisms of Its Regulation
A larger pool of monocytes in the circulation has emerged as an independent risk factor for coronary artery disease in humans, 67, 68 in concert with data indicating that monocytosis characterizes atherosclerosis in mice and is proportional to hypercholesterolemia. 17, 27 Thus, control of the circulating monocyte pool could provide means to affect the rate of disease advance. The mechanism behind hypercholesterolemia as a driver for monocytosis involves regulation of stem cell cycling by cholesterol in the membrane (Table 3) . 69 Molecules that support cholesterol efflux, including ABC transporters ABCA1 and ABCG1, and high-density lipoprotein as an acceptor of cholesterol exported by these molecules suppress proliferation of hematopoietic progenitors that ultimately account for the marked myelopoiesis that characterizes hypercholesterolemic mice. Control of proliferation is cell autonomous, and endogenous production of apolipoprotein E (apoE) is a key regulator (Table 3) . 70 Clinical evidence arising from patients with low high-density lipoprotein or hypercholesterolemia upholds the relevance of this paradigm to man. 71, 72 The cell autonomous role of apoE in regulating the size of the monocyte pool represents a novel mechanism by which apoE confers an atheroprotective state (Table 3) . We have long recognized that the absence of apoE on chylomicrons affects their clearance and promotes accumulation of very-low-density lipoprotein in apoE-deficient (apoE −/− ) mice. Now it is clear that apoE has other critical roles. In its absence, apoA1 associates not with high-density lipoprotein but with very-low-density lipoprotein, causing high-density lipoprotein to become less effective at promoting cholesterol efflux. 73 Macrophagederived apoE is sufficient to correct these changes in lipid profiles, indicating that macrophages can be a pivotal source of apoE. It is also thought that macrophage phenotype, particularly shifts between canonical M1 macrophages and M2 macrophages, 76, 77 is regulated by apoE so that lesions accumulate more atheroprotective M2 macrophages. 75 In our view, this claim needs deeper analysis to be substantiated. However, the role of apoE in controlling monocyte pool size is compelling.
Several other triggers contribute to high levels of circulating monocytes that in turn predispose to aggravated atherosclerosis, presumably through making more monocytes available for recruitment into plaques. These triggers include hyperglycemia and stimulation of the sympathetic nervous system that controls release of hematopoietic progenitors from the bone marrow. 78 By establishing an unwanted vicious cycle, stimulation of the sympathetic nervous system and the monocytosis that it induces explains a worsening of atherosclerosis after myocardial infarction. 78 Such worsening could contribute to the increased risk of a second cardiovascular event after a first event.
Although some studies of experimental atherosclerosis have shown that the density of monocytes in the blood correlates with the extent of monocyte infiltration into plaques 17, 27, 79 and overall macrophage burden, 80 it remains an assumption that the reason why monocytosis is clinically associated with increased cardiovascular disease is because of more monocytes available in the blood to gain access to plaques. There may be an array of other actions performed by monocytes that affect cardiovascular disease, or monocytosis may simply correlate with other changes that more directly affect atherosclerosis.
Origin of Foam Cells
We highlight the possibility that monocytosis may not be directly related to recruitment of monocytes to atherosclerotic plaques because of the surprising findings of a recent study that indicated plaque macrophages are mainly sustained in advanced experimental disease by local proliferation rather than recruitment of new monocytes on an ongoing basis, 81 a study more extensively discussed elsewhere. 82 These new data, taken at face value, seem to de-emphasize the importance Besides proliferation, there are other possible mechanisms in atherosclerosis that may contribute to the generation of foam cells in plaques independent of monocyte recruitment. First, like prelesional sites, some of the MPs in advancing atherosclerotic plaques may be DCs and, therefore, not derived from monocytes, and these DCs may accumulate lipids to become foam cells. 36 However, distinguishing plaque macrophages from DCs is more challenging than it is in some other tissues. In the mouse, standardized criteria are lacking and different laboratories, therefore, use nonstandardized strategies for identifying DCs. 7, 12, 36, 39, 83 CD11c is also expressed by some monocytes in models of atherosclerosis, 84 confusing the issue of which cells are DCs. Future studies are needed to better distinguish macrophages from DCs not just in early disease but in established disease as well. A specialized type of DC, the plasmacytoid DC, is known for its potent production of type I interferon. Several articles indicate that it plays a role in atherosclerosis, although whether these cells promote disease or suppress it is unsettled, with literature currently coming to disparate conclusions. 85, 86 They have not been found in the intima of murine arteries before or during atherosclerosis. 85, 86 Whatever their role, plasmacytoid DCs likely function outside of the plaque environment when they modulate disease.
An additional mechanism for the generation of foam cells in plaque unrelated to monocyte recruitment is the conversion of smooth muscle cells (SMCs) to foam cells that bear canonical markers of macrophages, such as CD68. 87 Again, more work is needed to determine whether and how significantly this mechanism of SMC-to-macrophage transition affects atherosclerosis progression. The issue receives less attention experimentally than it may deserve, considering that SMCs often function to stabilize plaques and guard against rupture. The origination of just a part of the plaque macrophage pool from SMCs is significant not only because it could build up macrophage numbers that can promote plaque rupture but also because it simultaneously reduces the number of cells that protect plaque. That is, the potential of this differentiation mechanism to affect atherosclerosis is seen more clearly when one considers the macrophage: SMC ratio rather than the fraction of macrophages derived from SMCs because both the numerator and the denominator of the ratio are altered in opposing directions by the event of a SMC differentiating to a macrophage.
Links Between Cholesterol and Macrophage Accumulation in Plaques
Macrophages are especially efficient at taking up and storing cholesterol in esterified form within the cytoplasm. Although it was long thought that the accumulation of cholesterol esters in macrophages would itself be a proinflammatory event, accumulation of cholesterol in peritoneal macrophages of LDLR −/− mice reveals that cholesterol accumulation is anti-inflammatory through the activation of liver X receptor that in turn stems from the robust accumulation of desmosterol in the cholesterol-loaded cells. 88 Thus, it is clear that cholesterol loading of macrophages is not inherently inflammatory. This observation fits with evidence that uptake of cholesterol through individual scavengers receptors does not greatly modify the rate of atherosclerosis development. 89 However, there are several mechanisms that link cholesterol with increased macrophage activation and accumulation in atherosclerosis (Figure) .
First, when macrophages are unable to efflux cholesterol appropriately, loading with cholesterol is proinflammatory and proatherogenic. The selective deletion of ABC-type cholesterol transporters ABCA1 and ABCG1 from macrophages that express Cre downstream of Lyz2 promoter activation (Lyz2-Cre×ABCA1 fl/fl ×ABCG1 fl/fl ) leads to monocytosis, activated macrophages in plaques, and increased atherosclerosis. 90 The Lyz2 promoter (sometimes called Lys-M) is expressed in nearly all macrophages and also in about half of monocytes and DCs, 91 as well as in ≈5% of stem cells. 92 Second, some toll-like receptors (TLRs) are thought to be bound and triggered by oxidized lipoprotein. TLR2 and TLR6 act as coreceptors along with CD36 for oxidized lowdensity lipoprotein, 93 and TLR engagement efficiently and robustly induces macrophage activation. 94 The role of TLR2 in atherosclerosis is most likely because of TLR2 activation in endothelium rather than bone marrow-derived cells, such as macrophages. 95 However, deficiency in TLR4 also modestly reduces atherosclerosis. 96 When the TLR adaptors TRIF or TRAM are absent from donor bone marrow cells used to reconstitute LDLR −/− mice, atherosclerosis is reduced, 97 suggesting that TLR signaling in the hematopoietic compartment contributes to atherosclerosis. Furthermore, other receptors including CD36, CD14, and C-reactive protein may bind to oxidized phospholipids to mediate proinflammatory roles in the absence of TLR signaling, 98 supporting the concept that oxidized phospholipids sustain atherosclerosis.
Activated TLRs ultimately trigger the transcription factor nuclear factor (NF)-κB, in turn associated with the transcription of pro-and anti-inflammatory genes. The role of NF-κB in atherosclerosis is complex, because depending on how it is inactivated, different results are obtained. 99, 100 Specifically, macrophage-selective deletion of IκB kinase 2 to prevent NF-κB activation surprisingly does not attenuate atherosclerosis. Instead, it makes it worse, arguably because the loss of anti-inflammatory cytokines like IL-10 supersedes the loss of proinflammatory cytokines. 99 However, when the NF-κB subunit p50 is missing in all hematopoietic cells of LDLR −/− mice, a condition generated through bone marrow transplant, atherosclerosis is attenuated. 100 In this scenario, it may not be macrophage NF-κB that drives atherogenesis and progression because other types of leukocytes would also lack NF-κB in the experimental design. Moreover, an often overlooked issue associated with the study of mice lacking the p50 NF-κB subunit is that ERK signaling is impaired. That is, the p50-deficient mouse lacks the precursor for p50, p105, and p105 is necessary for the stability of the mitogen-activated protein kinase ERK1/ERK2. Additional triggering of mitogen-activated protein kinases is necessary. 102 Furthermore, ERK signaling has been reported to be integral to STAT1 signaling downstream of interferon γ, 103 a cytokine that serves as a critical driver for macrophage activation in general and for atherosclerosis development and progression. 104 Thus, it is possible that the apparent role for NF-κB in atherosclerosis is not because of its role in macrophages or is more related to a role for ERK signaling during STAT1 activation. 103 Alternatively, phospho-STAT1 and NF-κB can cooperate to regulate expression of genes like intercellular adhesion molecule 1 and inducible nitric oxide synthase (Figure) . 103 However, STAT1 deficiency alone seems to suppress macrophage death in plaques but not plaque progression. 105 Thus, although it is highly likely that NF-κB contributes importantly to driving atherosclerosis, it is unclear if its activation is sufficient or whether expression within macrophages is the key driver.
A third, but still related, concept related to macrophage proinflammatory action in atherosclerosis emerged from considering the potential role of small crystals that form from free cholesterol. 106 Activation of the NLRP3 inflammasome generates active IL-1β or IL-18, central proinflammatory mediators that have been linked to atherosclerosis and many other inflammatory diseases, through cleavage of pro-IL1 or pro-IL18 by caspase 1/11. 107 The NLRP3 inflammasome is a sensor for various crystals such as those in gout, as well as cholesterol crystals, 106, 108 and in turn activates caspase 1 or caspase 11.
107 NLRP3 activation cannot generate active IL-1β/IL-18 if its substrates pro-IL1β or pro-IL18 have not been induced. Thus, the generation of the active forms of these cytokines requires 2 steps. The first step is called priming and mechanistically requires the induction of mRNA and translated pro-IL1 through signals such as those that might include but not be limited to signals from TLR ligands or proinflammatory oxidized phospholipids discussed above. The second step is the activation of the inflammasome by a ligand, often a crystal, small enough to be engulfed by macrophages, which leads to activation of caspase 1. In addition to being activated by crystals, inflammasome activation can be triggered by extracellular ATP, 106 a signal that increases in an environment of necrotic cells. Thus, because both cholesterol crystal and Figure. Proposed signaling pathways in macrophages that link cholesterol to their accumulation in atherosclerotic plaques. Two major drivers of increased macrophage accumulation in plaques are proliferation (left) and recruitment (right). The quantitative importance of macrophage proliferation in overall macrophage accumulation has only recently been appreciated so remains understudied. To date, only signaling from scavenger receptor A (SR-A) has been associated with proliferation. Signals proposed to regulate macrophage accumulation are many (right) and include binding of oxidized low-density lipoprotein (LDL) to toll-like receptor (TLR)s that in turn activate nuclear factor (NF)-κB. Transporters such as ATP-binding cassette (ABC)A1 at the plasma membrane may control the assembly of signaling molecules through regulation of membrane cholesterol. The inflammasome, coupled with TLR activation, generates interleukin (IL)-1β, and free fatty acid signaling triggers IL-1α production in an inflammasome-independent manner. Signaling through interferon (IFN) γ receptor activates STAT1 that in turn influences the expression of genes including chemokines such as CXLC10 and CCL5 and adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1). IL-1α and IL-1β are classic proinflammatory cytokines that target the endothelium to promote, for instance, recruitment of monocytes. Apo A indicates apolipoprotein A; HDL, high-density lipoprotein; and IRF, interferon response factor. by guest on October 7, 2017 http://circres.ahajournals.org/ Downloaded from necrotic cells are prominent features within atherosclerotic plaques, the inflammasome is extremely relevant to the regulation of inflammation in plaque. Not all studies have been able to replicate the finding that the NLRP3 inflammasome mediates atherosclerosis, 109 and still others identify alternative mechanisms for NLRP3 as a mediator of atherosclerosis, including its induction in endothelium by hemodynamic changes. 35 Even if it does, the abundance of cholesterol crystals in early macrophages is startling. One wonders if the tiny crystals might not be as dense in vivo as originally reported but instead were triggered by a drop in temperature resulting from chilling of the atherosclerotic tissue during preparation and its examination at room temperature. The role of IL-1β in atherosclerosis has been recently questioned in a study that suggested that the reduced ability of IL-1β-deficient mice to secrete IL-1α accounts for the atheroprotection it affords. 110 IL-1β, however, drove inflammation in atherosclerosis and was induced by fatty acid-driven mitochondrial uncoupling and ensuing oxidative stress (Figure) . 110 Finally, an exciting but relatively unexplored potential connection between cholesterol and leukocyte recruitment is the identification of oxysterols 7α,25-hydroxycholesterol and 7α,27-hydroxycholesterol as ligands for the G-proteincoupled receptor gpr183 (Epstein-Barr virus induced 2).
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These ligands promote chemotaxis of B lymphocytes and DCs. [113] [114] [115] [116] [117] The mRNA for this receptor is also expressed on Ly-6C + monocytes (http://www.immgen.org). No data have been published on whether this chemotactic form of cholesterol affects atherosclerosis.
The literature discussed above illustrates that multiple mechanisms may operate in linking cholesterol to an inflammatory stimulus that drives macrophage accumulation (Figure) . Do the mechanisms work together in a synergistic manner or does each contribute independently to atherosclerosis progression and be more or less relevant under different circumstances? Integrating these mechanisms and determining their direct relevance to monocyte recruitment or macrophage proliferation are challenges for the future. However, in many ways, the mechanisms proposed can already be integrated and seem to represent different aspects of the same inflammatory pathway. TLR engagement by oxidized lowdensity lipoprotein is one mechanism of priming the inflammasome, generating pro-IL1β or pro-IL18, and crystals of cholesterol might carry out the second step of giving rise to the active form of these cytokines. Interestingly, the failure to efflux cholesterol heightens signaling through TLRs, possibly by altering signaling domains that complex with cholesterol in the membrane. 90, 118, 119 Thus, as the Figure shows the mechanisms that generate proinflammatory intermediates such as IL-1β or IL-1α that in turn act on the endothelium to promote recruitment of monocytes might involve several integrated steps ranging from control of cholesterol efflux to responses normally associated with infection. Together, these pathways particularly regulate plaque macrophage burden as it relates to macrophage recruitment. It remains unclear how these pathways affect macrophage proliferation in plaques because only scavenger receptor A signaling has to date been associated with this apparently critical mechanism for regulating macrophage burden in atherosclerotic plaque (Figure) .
Macrophage Balance Sheet: Ongoing Loss of Macrophages From Atherosclerotic Lesions
Beyond events that control the ongoing increase of macrophage numbers in plaques, from recruitment of monocytes to proliferation of macrophages, alteration of basic cellular mechanisms that normally control macrophage removal could affect overall macrophage burden. In the immune system, major pathways of cell removal are death and migratory emigration to other anatomic sites. Among MPs, DCs are best known to clear from organs by emigrating to draining lymph nodes on activation. 120 At least hypothetically, transdifferentiation of macrophages could also effectively remove them, such as differentiation of macrophages to SMCs, but such a mechanism has not been documented. Thus, we are left to consider the role of death and emigration as modifiers of macrophage burden. Emigration will be discussed more extensively in the section on disease reversal below. However, the literature is consistent in concluding that macrophages are not prone to emigrate out of plaques during progression of atherosclerosis, and thus emigration does not seem to be a major modifier of overall macrophage burden as plaques enlarge.
By contrast, cell death is a well-documented means of removing cells from organs during development and during disease. Death of macrophages in atherosclerosis is made more complex by the fact that clearance of apoptotic cells, by other macrophages that play a key role in efferocytosis, is impaired. 121 Failed clearance of dying cells promotes inflammation and even autoimmunity in a variety of contexts. 122 In atherosclerosis, death of macrophages has dual consequences depending on the disease stage. At early stages, when efferocytosis is not yet blocked, failure of macrophages to die efficiently leads to larger plaques and increased macrophage burden, indicating that apoptosis of macrophages is a key determinant in regulating the size of the macrophage pool. However, at later stages of disease, particularly when efferocytosis is no longer efficient, reduced macrophage death seems to reduce disease progression likely because death in the absence of clearance builds necrotic core and promotes inflammation. 123 However, treatments that are systemically effective in inducing macrophage apoptosis lead to a loss of the liver macrophage (Kupffer cell) pool and increase plasma cholesterol, erasing the anticipated positive effect on inducing early plaque macrophage death locally. 
Plaque Regression and Macrophage Removal From Plaques
A significant fraction of the human population is affected by atherosclerosis that is established. These individuals face the challenge of reducing their risk for developing clinically significant disease. An attractive goal in therapy would be to reverse disease burden in patients at risk. Because macrophages are key components in the plaque and are associated with plaque rupture, removal of macrophages from plaques is a logical approach in generating stable plaque even if plaque regression defined as a reduction in plaque area is not achievable. The question is how macrophage burden be reduced? In principle, all of the cellular mechanisms listed above that control ongoing increases in macrophages may participate in disease reversal. The concept that emigration of macrophages might be relevant to their removal from plaques was introduced by Ross Gerrity in the early 1980s. 125 He captured electron micrographs of foam cells appearing to pass through the transendothelial junction of arterial endothelium. The images were static but suggestive of migratory egress from plaques because he reasonably argued that incoming monocytes, which might also be identified in the act of transendothelial migration, would not arrive already so loaded with lipid droplets as the MPs he imaged obviously were. Alternatives to his interpretation might include the possibility that the cells he imaged were not necessarily emigrating out but instead simply extending pseudopods into the arterial lumen, a process that has now been documented in the artery wall 39 and elsewhere. 126, 127 We went on to propose and pursue the idea of emigration as a key modifier of macrophage burden in plaques when we reported evidence that MPs emigrated from transplanted arteries during disease reversal conditions but not in disease progression conditions. 22 We also observed that DCs from skin of atherogenic mice have strikingly reduced ability to emigrate to draining lymph nodes. 128 Underlying our belief that emigration of macrophages from plaques might be relevant to their clearance was not only the work of Ross Gerrity. We were also struck by a report that concluded that macrophage clearance during resolution of inflammation induced in the peritoneum by injection of thioglycollate required that macrophages emigrate to draining lymph nodes. 129 However, we have recently repeated this model using new, more quantitative techniques, and we found that the mode of clearance is far more reliant on local death than on emigration to lymph nodes, 130 leading us to conclude that macrophage emigration may not be a key feature of resolution after all.
Although there is agreement that macrophages are not prone to emigrate out of plaques during progression of atherosclerosis, the literature is less unified when it comes to examination of lesion regression. Besides our recent work in the acute inflammatory model of thioglycollate-induced peritonitis where we concluded macrophage removal was more dependent on local death than emigration, we have found no evidence for robust emigration from plaques in models of atherosclerosis regression other than the surgical model previously mentioned. Specifically, we developed a method, conceptually detailed elsewhere, 130 that can monitor phagocyte trafficking out of plaques using nonbiodegradable particles, where the loss of these particles from plaques during regression would signal emigration from plaques and provide information on its kinetics and magnitude. It is critical that the tracer particles are not biodegradable so that events like cell death and protein turnover do not influence their presence in the plaque. The method is useful to track monocyte entrance into plaques, as well as their emigration, and it has been used by multiple groups interested to chart the emigratory behavior of macrophages from plaques. We have used the method in a model of atherosclerosis regression where apoE −/− mice were treated with apoE vectors, monitoring monocyte entrance and macrophage egress from atherosclerotic plaques at the aortic root and aortic sinus. Neither anatomic site showed evidence of egress marked by a loss of the bead-based phagocytic tracer in the plaque, but reduction of macrophages in plaques was instead preceded by a profound reduction in monocyte recruitment to plaques. Thus, we concluded that macrophage egress is not essential for contraction of macrophages from plaques and that such contraction more closely correlates with cessation in monocyte recruitment. Blockade in new monocyte entry could only remove macrophages if there was some ongoing death, so that dying macrophages were not replaced by newly arriving cells. Apoptotic macrophages were not obviously increased in this model of regression but nonetheless occurred. A similar explanation for reduction in macrophage content in apoE hypomorphic mice induced to express apoE was recently found by Eberlé et al. 80 Other studies, however, have used the same bead-tracking technique to identify evidence of macrophage egress from plaques. The conditions associated with a positive detection of macrophage emigration from plaques include examination of the aortic arch after transplant into recipient mice, 131, 132 studies in the aortic arch of LDLR −/− mice lacking netrin, 133 LDLR −/− mice switched from a cholesterol-enriched diet that promotes atherosclerosis to a standard chow diet that allows for regression, or studies in the aortic sinus of apoE −/− mice that were treated with statins to promote macrophage contraction from plaques that remained stable in overall area. 134 Furthermore, in addition to promoting egress, statins reduce monocyte recruitment and reign in monocytosis in apoE −/− mice. 17 In LDLR −/− mice transitioned to a low-cholesterol diet from a high-cholesterol diet, monocyte recruitment is also reduced. 79 This reduction fails during hyperglycemia, whereas egress continues, so plaque macrophage content more closely mirrored the changes in monocyte recruitment than egress.
The discrepancy over whether macrophages do or do not exit plaques during disease regression needs clarifying through additional research. First, these pathways comprise natural therapeutic targets, a way to reduce disease burden and risk in individuals already affected by atherosclerosis. Gaining clarity on the most relevant pathways for removing macrophages will greatly facilitate moving toward rational therapeutics.
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Second, analysis of the role of molecular mediators affecting atherosclerosis will naturally be interpreted in light of what is known about cellular events in the disease. In atherosclerosis, it is often easier to study the effect of genetic deficiency by asking how deficiency in a molecule affects atherosclerosis than it is to follow the related cellular events. For example, several studies point to a role for the G-protein-coupled receptor, CCR7, in modifying atherosclerosis. One indicates that loss of CCR7 in apoE −/− mice exacerbates disease. 135 When we crossed apoE −/− mice with CCR7 −/− mice, no significant change in lesion area was noted, but there was a trend toward disease protection, 28 seemingly akin to LDLR −/− CCR7 −/− mice that were protected from atherosclerosis in yet another study. 136 CCR7 has critical roles in T-cell trafficking and responses, and there is direct evidence from competition studies that its expression on T cells (or not) modifies T-cell trafficking. 136 However, other literature on CCR7 and atherosclerosis has focused on its possible role in mediating macrophage egress from plaques. 23, 131, 132, 134 The major evidence is increased CCR7 mRNA during regression, but the cells expressing CCR7 remain uncertain-are they macrophages, DCs, T cells, or a mixture of all? Some studies find no correlations or role for CCR7 in bringing about macrophage contraction. 28, 80, 137 New methodology, including new strains of mice recently developed, 138 that could distinguish CCR7 on T cells from other immune cells would be helpful in clarifying the confusing role of CCR7 in atherosclerosis and its regression.
Finally, settling the issue of whether macrophage do or do not have the capacity to leave atherosclerotic plaques affects our understanding of macrophage biology beyond the realm of atherosclerosis. Given the consensus that macrophages do not leave plaques during disease progression, the unanswered question is whether the inability of macrophages to leave plaques typifies macrophage behavior in general or is a pathological feature that facilitates the chronic inflammation that characterizes atherosclerosis. Our reanalysis of the role of emigration to lymph nodes in a simple, acute inflammatory model to try to get better insight into this fundamental question leaves us skeptical of the migration paradigm for macrophage removal. 130 So, what other information exists in the literature? Claims of macrophage migration have been made for decades, but early work was fraught with the inability to distinguish macrophages from monocytes and DCs, so it is not completely clear whether macrophages in tissues, beyond a small minority, are truly able to mobilize from tissues under any conditions. Surprisingly, little recent literature directly speaks to this issue. However, intravital imaging of macrophages in murine liver granulomas concludes that during a period of days to weeks, net macrophage displacement is minimal. 139 Monocytes newly recruited to tissues, however, seem to be motile, exhibiting the capacity to pass into a tissue and out through its lymphatic vasculature without even differentiating to a macrophage. 50 Thus, at present, we currently favor the concept that monocytes and DCs, but not macrophages, are motile cells with the capacity to emigrate out of tissues. If MPs can emigrate from atherosclerotic plaques, we predict that the cells doing so are either DCs or monocytes that have yet to differentiate to bona fide macrophages, but that macrophages do not egress.
From the data indicating retention of macrophages not just in plaques but also other organs, 130, 139 one wonders why are macrophages relatively confined to a territory within a tissue in contrast to DCs or monocytes. The answer is not yet obvious. The possible answers range from inherently different organization and signaling within the cytoskeleton, failure of macrophages to express key receptors like CCR7
140 that promote motility in response to chemotactic cues, or ubiquitous retention signals for macrophages within the matrix of tissues. I favor the first possibility because there are at least rare instances when emigration to lymph nodes is independent of CCR7, 130 but it is possible that tissues actively retain macrophages through signals like those provided by the neural guidance cue receptor netrin-1 in atherosclerotic plaque. 133 It would be relevant, as a next step, to determine if macrophage density in a range of organs is reduced in the netrin-deficient mouse under homeostatic conditions or if retention of macrophages in other inflammatory reactions is altered. From this vantage point, might netrin or other signaling pathways capable of retaining macrophages in tissues be a normal, rather than pathological, process?
Frontiers and Future Directions
Huge progress has been made in the past several years in studying the cellular and molecular mechanisms that control macrophage burden in atherosclerotic plaques. Although debate is active and ongoing on some of the basic mechanisms involved, such as the relative role of proliferation versus monocyte recruitment in generating macrophages and the relative roles of egress versus cessation of proliferation or recruitment as an approach to reduce macrophages during disease regression, the rapid pace of research in this area and the new tools under development to address them bodes well for soon solving these mysteries. Understanding the mechanisms that regulate macrophage burden will then allow the field to turn to other critical questions such as how is the control of macrophage burden in plaques intermingled with the role of the adaptive arm of immunity in atherosclerosis. This is a subject that only a few studies have begun to address. 83 Likely, all regulators of atherosclerosis including adaptive immune effectors somehow affect macrophage burden in plaques, but currently the connections are largely unexplored. We anxiously work and wait to witness what the next decade of research will reveal.
